Bilevel-Bilateral Sacral Erector Spinae Plane Block for Chronic Pain Management: A Case Report and Short Literature Review

Kronik Ağrı Tedavisinde Bilevel Bilateral Sakral Erektör Spina Plan Bloğu: Olgu sunumu ve Literatürün Kısa Gözden Geçirilmesi

Alper Kilicaslan¹, Esra Goger¹, Feride Karakus¹, Ruhiye Reisli¹

¹Department of Anaesthesiology and Reanimation, Meram Faculty of Medicine, Necmettin Erbakan University, Konya, Turkey


INTRODUCTION

Erector spinae plane block (ESPB), one of the popular regional anesthesia techniques in recent years, has first been used for upper thoracic neuropathic pain (1). Later, it has been used in many different indications for both acute and chronic pain treatment at different lower thoracic and lumbar levels (2). Only recently, various cases in which ESPB was administered due to acute pain at the sacral level have been reported (3-8).

The treatment of end-stage cancer pain is challenging, and when adverse effects arising from especially the use of opioids develop, they usually require interventional approaches. In limited number of case reports related to the use of ESPB due to cancer pain, ESPB has been stated to provide sufficient and continuous analgesia (9-11). To our knowledge, there is no previous report in which sacral ESPB has been used due to chronic cancer pain. Considering the effectiveness of ESPB in chronic pain at upper levels, we have hypothesized that ESPB performed at sacral level would provide effective analgesia in chronic anorectal pain.

CASE

A written informed consent was obtained from the patient. A 62-year-old male patient had been diagnosed with inoperable squamous cell carcinoma of the anal canal in 2007. The patient had undergone multiple treatments, including surgery, radiotherapy, and chemotherapy, but the disease progressed and the patient was referred to our service for pain management.

The patient had been experiencing severe intermittent perianal pain for the last 6 months. The pain was described as burning, shooting, and cramping, and was exacerbated by any movement or pressure. The patient reported a significant impact on his quality of life, affecting his ability to perform daily activities and social interactions.

A detailed physical examination revealed tenderness and hyperalgesia in the perianal region. The medical history was notable for a history of smoking and alcohol abuse. The patient had no history of allergies or other medical conditions.

After a comprehensive evaluation, including a thorough history and physical examination, an interdisciplinary team consisting of a pain management specialist, an anesthesiologist, and a radiologist, proposed the use of sacral ESPB for pain management.

The procedure was performed under sterile conditions following proper disinfection protocols. The patient was placed in the lateral decubitus position with the lower body away from the examining team. The sacral region was prepped and draped in a sterile manner.

Anatomical landmarks were confirmed using real-time ultrasound imaging. The transverse process of the S2 vertebral body was identified as the target for the needle insertion. A 22-gauge, 10 cm spinal needle was advanced in a cephalad and lateral direction towards the transverse process under ultrasound guidance. Once the needle tip reached the transverse process, 40 mL of 0.5% ropivacaine was injected with a slow and steady technique. The needle was then withdrawn, and the patient was observed for any signs of spread or complications.

The patient reported immediate and significant reduction in pain intensity. The analgesia lasted for 24 hours, and the patient was able to resume his daily activities without any restrictions. The patient was satisfied with the outcome and requested further treatments.

The patient was discharged on the same day with specific instructions for pain management and follow-up appointments. The patient’s pain was managed effectively with a combination of tramadol and acetaminophen, and the patient was instructed to return for further treatments as needed.

DISCUSSION

The use of sacral ESPB as a treatment for chronic pain in the perianal region has been reported in limited case reports (3-8). ESPB provides effective analgesia by blocking the sensory nerves from the lower thoracic and lumbar regions, including the sacral region.

The use of sacral ESPB in the management of chronic anorectal pain has several advantages. The procedure is minimally invasive and can be performed in an outpatient setting. ESPB provides long-lasting analgesia, which can help in reducing the reliance on opioids and their associated side effects. ESPB can be performed using real-time ultrasound guidance, which provides accurate and effective needle placement.

Further research is needed to establish the effectiveness and safety of sacral ESPB in the management of chronic anorectal pain. The use of sacral ESPB in chronic anal pain should be considered as an alternative to opioids and other analgesic medications. Further studies are needed to evaluate the long-term effects of sacral ESPB and to compare it with other pain management techniques.

REFERENCES


Disclosure: None of the authors has a financial interest in any of the products, devices, or drugs mentioned in this article. The research was not sponsored by an outside organization. All authors have agreed to allow full access to the primary data and to allow the journal to review the data if requested.
the patient for the procedure and the publication of data. A 62-year-old, 70 kg male patient was admitted to the department of algology with the complaint of intermittent severe pain in the perianal and gluteal region (S2-S5 dermatomes). The patient had undergone anorectal surgery due to rectal cancer (adenocarcinoma) 12 months ago; however, he reported that the pain continued intermittently and was exacerbated during the last two days. So, the patient was evaluated as the numerical rating scale (NRS) of 8-9/10, and the history revealed ejection fraction (EF) <30%, atrial fibrillation (AF) and the use of anticoagulant. We primarily scheduled to perform bilevel-bilateral sacral ESPB for achieving an immediate acute pain relief. After confirming that the case did not have a coagulation disorder, the patient was placed into the prone position in the pain intervention room, and administered with 1 mg bolus of midazolam and 50 μg fentanyl prior to the block performance.

After the block site and ultrasound (USG) probe were sterilized, a linear transducer (10-18 MHz, Esaote My Lab 30, Genoa, Italy) was centered on the L5 vertebra spinous process in the midline. In order to determine the intended level, the transducer was shifted towards the caudal, and the second median crest was imaged. Then, the transducer was laterally moved 3-4 cm, and the intermediate crest (IC) was detected in the parasagittal plane. A 21-gauge, 100-mm block needle (Pajunk, Geisingen, Germany) was inserted in the plane until it was contacted with the bone from the cranial to caudal. While a half of local anesthesia mixture (25 mL of 0.25% bupivacaine and 4 mg of dexamethasone) was administered into the interfascial plane deep to multifidus muscle and erector spinae aponeurosis at the S2-S3 level. We noticed the cranio-caudal spread and that the muscle was elevated above the bone. The needle was then withdrawn and re-directed towards the caudal. The remaining half of the local anesthesia mixture was injected into the same interfascial plane at the S4-S5 level (Fig. 1). The same procedure was performed for the opposite side with the same volume, and no complications were observed. A total of 50 mL of local anesthesia mixture was used for bilevel-bilateral sacral ESPB administered with two injection points. Twenty minutes after the injection, the NRS score was seen to decrease to 2/10. The assessment at 12nd hour revealed a sensory blockage (pinprick) between the L5-S4 dermatomes, and the NRS was still 2/10. At the end of 24th hour, the NRS score was 3-4/10, and the patient needed no rescue analgesics or other opioids. The patient was discharged with oral pregabalin 75 mg (2x1) and tramadol 100 mg tablets.

DISCUSSION

Our limited experience demonstrates that bilevel sacral ESPB is an easy and effective method in the treatment of perianal chronic intermittent pain. Our case had chronic complex pain following anorectal surgery due to rectal cancer. The treatment of end-stage cancer pain is challenging due to the side effects of opioids and its nature in a way to require interventional approaches. It has been reported
that persistent pain may develop at a rate of 1.5-3.5% after the transanal rectal resection (12). The underlying cause is primarily taken into consideration in terms of the treatment of chronic anorectal pain; unfortunately, there is no consensus concerning the treatment process (13). Based on literature, such invasive procedures as caudal, epidural blocks, sacral nerve stimulation and local anesthetic infiltration have been performed in addition to the medical treatment (14,15). In performing sacral ESPB, local anesthetic is administered to the facial plane under the erector spinae aponeurosis and multifidus muscle, as in the thoracolumbar region; however, it is a quite different block due to anatomical differences. Erector spinae muscles overlay on the transverse processes of the lumbar vertebrae and continue over the sacral laminae. The field of application and sonographic images are more synonymous with the retrolaminar region. Therefore, Hamilton stated that the terms "sacral retrolaminar block" or "sacral multifidus plane block" could be applied to this technique (16).

Although quite limited number of case reports related to sacral ESPB have been published, no randomized controlled trials are currently available. However, sacral ESP blocks have been performed at different levels to the cases from different age groups. Therefore, we decided to review clinical data based on literature in order to grasp the general features of sacral ESPB, and so searched and reviewed on PubMed, “Google Scholar” and “Web of Science” by using the key words of “sacral erector spinae plane block” between January 2017 and December 2019.

The following information was extracted from the five case reports we obtained: (a) the indications for the block, (b) the level for which the block was performed and anatomical localization, (c) the type, dose and concentration of local anesthetics, (e) the type of the block (single shot or catheter placement), (f) the side effects, (g) adverse events, and (i) the results. The data obtained from the studies are presented in Table 1, and no adverse events or side effects were reported in any case reports. The single shot technique was used in all case reports. Three different injection sites have been identified for sacral ESPB in various case reports published so far (Fig. 2). In the study by Tulgar et al., it was reported that a sensory blockage was obtained in L5 and the first three posterior branches of sacral nerves as the result of ESPB performed at the second sacral level. On the other hand, these authors advocated that the injected agents did not spread to the anterior branches of the sacral nerve or the sacral plexus (3). In later reports, however, different results were reported to be obtained. In another study by Aksu and Gurkan, it was reported that a local anesthetic at a dose of 1 mL/kg (8 mL of 0.25% bupivacaine) was administered with a single injection from the midline at the level of 4rd median sacral crest to a 6-month infant. In the same study, the authors also reported that there was no need unexpectedly for additional analgesics during the first 24 hours, and claimed the epidural spread (5).

In our study, however, we obtained clinical evidence regarding the blockade of the dorsal and ventral branches of the spinal nerves after bilevel-bilateral sacral ESPB we performed with relatively higher volumes. In both the present case report and our previously published reports (7,8), we observed the spread of local anesthetic agent to cranial and caudal, to the lumbar region under the erector spinae muscle, as similar to the finding reported by Piraccini et al. (4). Thus, we consider the injected material may have reached the anterior branches of the spinal nerves. However, the mechanism of possible epidural diffusion of the enjectate administered from the midline and S4 level still remains unclear. If different mechanisms of action were detected through future studies, the naming or definition could

**Figure 2.** Red (4,7), yellow (3) and blue dots (5,6) show the basic illustration of defined injection points of the sacral erector spinae plane block.
be changed, and novel classifications, such as upper, lower or lateral sacral ESPB may be termed. Also, the differences related to the anatomy of pediatric population and the permeability of the tissues may be other issues to be considered. The main limitation of our study is that previous reports are mostly case reports, meaning low-grade evidence. There are no randomized controlled trials in literature.

Sacral ESPB seems to be an easy technique because of the absence of large vessel and nerve structures at the facial plane, and because the defined target points are superficial. However, it is obvious that further studies are needed to elucidate the side effects and unexpected events.

**CONCLUSION**

As a result, sacral ESPB may be a promising method to relieve the acute postoperative and chronic pain in light of previous case reports. However, many issues need to be clarified, such as the anatomical nomenclature, the application site, the volume of local anesthetics and the sensory blockade area. Due to the lack of clinical research, our review is currently unable to support the evidence and routine use of sacral ESPB. We consider that anatomical radiological and clinical studies are needed to elucidate the efficacy and mechanism of action of sacral ESPB.

**Conflict of interest:** Authors declare that there is no conflict of interest between the authors of the article.

**Financial conflict of interest:** Authors declare that they did not receive any financial support in this study.

**Address correspondence to:** Alper Kilicaslan, Necmettin Erbakan University, Meram Faculty of Medicine, Department of Anesthesiology and Reanimation 42080, Meram, Konya, Turkey

**Mobile number:** +90 0505 378 03 76

**E-mail:** dralperkilicaslan@gmail.com

**REFERENCES**


---

**Table 1. Information extracted from case reports related to sacral erector spinae plane block**

<table>
<thead>
<tr>
<th>Authors (Reference)</th>
<th>Indication</th>
<th>Patients' age</th>
<th>Sacral level and localisation of block</th>
<th>Volume, type of local anesthetic and additives</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tulgar S</td>
<td>Pilonidal sinus surgery, PPM</td>
<td>28 years-M</td>
<td>S2, Intermediate sacral crest, bilateral</td>
<td>10 mL Bupivacaine 0.5%, 5 mL Lidocaine 2%, normal saline for each side (totally 40 mL)</td>
<td>NRS 0/10 after 40 min of block NRS &lt;3/10 in first 13 hours</td>
</tr>
<tr>
<td>Piraccini E</td>
<td>Acute L5 radicular pain</td>
<td>67 years-M</td>
<td>S1, Intermediate sacral crest</td>
<td>Ropivacaine 30 mg and Triamcinolone 40 mg (totally 15 mL)</td>
<td>NRS 0/10 after 20 min of block NRS&lt;4/10 after 7 days</td>
</tr>
<tr>
<td>Aksu C</td>
<td>Hypospadias repair, PPM</td>
<td>6 months</td>
<td>S4, Median sacral crest</td>
<td>8 mL of 0.25% Bupivacaine (1 mL/kg)</td>
<td>FLACC 0 or 1 in 24 hours</td>
</tr>
<tr>
<td>Oksuz G</td>
<td>Anoplasty surgery, PPM</td>
<td>7 months</td>
<td>S4, Median sacral crest</td>
<td>9 ml 0.25% Bupivacaine (1 mL/kg)</td>
<td>FLACC 0 in first 24 hours</td>
</tr>
<tr>
<td>Kilicaslan A</td>
<td>Pelvic and sacral fracture surgery, PPM</td>
<td>Case 1: 69 years-M Case 2: 29 years-M</td>
<td>S1, Intermediate sacral crest, bilateral</td>
<td>10 mL Bupivacaine 0.5%, 5 mL Lidocaine 2% and 5 mL normal saline for each side (totally 40 mL)</td>
<td>Case 1: VAS &lt;3/10 in first 14 hours Case 2: VAS 1/10 in first 12 hours VAS 4/10 at 24 h.</td>
</tr>
</tbody>
</table>

FLACC: Face, leg, activity, cry and consolability; M: Male; NRS: Numeric rating scale; PPM: Postoperative pain management; VAS: Visual analog scale


